This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Andersson, K. Articles by Dillner, J. Search for Related Content PubMed PubMed Citation Articles by Andersson, K. Articles by Dillner, J.

Seroreactivity to Cutaneous Human Papillomaviruses among Patients with Nonmelanoma Skin Cancer or Benign Skin Lesions

¹ Department of Medical Microbiology, Malmö University Hospital, Lund University, Malmö, Sweden; Divisions of ² Genome Modifications and Carcinogenesis and ³ Tumourvirus Characterization, Deutsches Krebsforschungszentrum, Heidelberg, Germany; ⁴ Laboratory of Viral Oncology, Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria; and ⁵ Medical Virology, Section Experimental Virology, University Hospital of Tübingen, Tübingen, Germany

Requests for reprints: Joakim Dillner, Department of Medical Microbiology, Malmö University Hospital, Lund University, Entrance 78, UMAS, SE-205 02 Malmö, Sweden. Phone: 46-40-338126; Fax: 46-40-337312. E-mail: joakim.dillner{at}med.lu.se

Cutaneous human papillomaviruses (HPV) are common in nonmelanoma skin cancers, benign skin lesions, and healthy skin. Increased seroprevalences for cutaneous HPV among nonmelanoma skin cancer patients have been described. To determine whether antibodies to cutaneous HPV are related to presence of the virus and/or to skin disease, we collected serum and biopsies from both lesions and healthy skin from 434 nonimmunosuppressed patients (72 squamous cell carcinomas, 160 basal cell carcinomas, 81 actinic keratoses, and 121 benign lesions). Biopsies were analyzed for HPV DNA by PCR, cloning, and sequencing. Serum antibodies to the major capsid protein L1 of HPV 1, 5, 6, 8, 9, 10, 15, 16, 20, 24, 32, 36, 38, and 57 as well as to the oncoproteins E6 and E7 of HPV 8 and 38 were detected using a multiplexed fluorescent bead-based assay. Type-specific seroprevalence among patients with the same type of HPV DNA (sensitivity of serology) varied from 0% to at most 28%. Presence of HPV DNA and antibodies to the same HPV type was not significantly correlated. However, seropositivity to any HPV type was significantly more common among patients positive for HPV DNA of any HPV type (odds ratio, 1.90; 95% confidence interval, 1.55-2.34). Seroprevalences were similar among the different patient groups but was, for most HPV types, somewhat higher among squamous cell carcinoma patients than among basal cell carcinoma patients (P < 0.01). In conclusion, additional studies are required to clarify the biological meaning of seropositivity as a marker of cutaneous HPV infection and skin disease. (Cancer Epidemiol Biomarkers Prev 2008;17(1):189–95)